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ABSTRACT 
 
Cellular therapy is emerging as a promising alternative to conventional immunosuppression 
in the fields of haematopoietic stem cell (HSC) transplantation, autoimmune disease and 
solid organ transplantation.  Determining the persistence of cell-based therapies in vivo is 
crucial to understanding their regulatory function and requires the combination of an 
extremely sensitive detection technique and a stable, long-lifetime cell labelling agent.  This 
paper reports the first application of laser ablation inductively coupled plasma mass 
spectrometry (LA-ICP-MS) to perform single cell detection of T cell populations relevant to 
cellular immunotherapy.  Purified human CD4+ T cells were labelled with commercially 
available Gd-based MRI contrast agents, Omniscan® and Dotarem®, which enabled 
passive loading of up to 108 Gd atoms per cell.  In mixed preparations of labelled and 
unlabelled cells, LA-ICP-MS was capable of enumerating labelled cells at close to the 
predicted ratio.  More importantly, LA-ICP-MS single cell analysis demonstrated that the 
cells retained sufficient label to remain detectable for up to 10 days post-labelling both in 
vitro and in vivo in an immunodeficient mouse model. 
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INTRODUCTION 
 
Cellular therapy with defined populations of regulatory immune cells is emerging as a 
clinically viable strategy to augment or replace conventional immunosuppression in the fields 
of haematopoietic stem cell (HSC) transplantation, autoimmune disease and solid organ 
transplantation where the major driver is improved therapy and a reduction in drug toxicities.  
Much of the optimism surrounding these approaches is based on data from a large number 
of diverse animal models which show unequivocally that cellular therapy can take advantage 
of endogenous regulatory mechanisms in the mammalian immune system.   
 
Phase I/II clinical trials have evaluated naturally occurring regulatory T cells (nTreg), in the 
context of graft-versus-host-disease (GVHD), a life-threatening complication of HSC 
transplantation1-3 and in paediatric patients with new-onset Type 1 diabetes.4  In solid-organ 
transplantation, an international consortium is currently seeking regulatory approval for the 
evaluation of several types of regulatory immune cells in living-donor kidney transplantation.  
Cell types under investigation in this study will include nTreg,5-7 Tr1 cells,8,9 dendritic cells,10 
and macrophages.11,12  
  
Determining the persistence and tissue distribution of the administered cells is essential for 
assessing their immunoregulatory effects in vivo but tracking therapeutic cells presents two 
significant challenges.  Firstly, in the majority of cases, the cellular therapy will be derived 
from the transplant donor in HSC transplantation, or from the recipient in the case of kidney 
transplantation.  Thus, in most cases the cells will be autologous with the immune system of 
the transplant recipient and therefore invisible to normal phenotypic methods of detection 
such as flow cytometry.  Secondly, at current planned doses, the administered cells will 
represent a small fraction of the recipient’s endogenous regulatory immune cells adding 
further to the problem of detection.  A solution to these two related problems would be the 
development of clinically acceptable (GMP) cell labelling techniques combined with a 
sensitive detection method, capable of detection of single cells and at very high cell 
detection efficiency. 
 
Contrast agents (CA) are frequently used in conjunction with clinical magnetic resonance 
imaging (MRI) to enhance the quality of images.  These agents typically consist of a 
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paramagnetic metal ion, such as Gd3+ or Fe2+/Fe3+, associated with a strong chelating 
ligand.13  Gadolinium based contrast agents are a particularly attractive option for cell 
labelling, due to their low background levels in the human body, and indeed several studies 
have reported their use as cellular labels for MRI tracking studies.14-16  However, whilst MRI 
is undoubtedly valuable for bulk imaging, the technique is currently incapable of providing 
the necessary sensitivity and spatial resolution for single cell monitoring. 
 
Laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) is a sensitive 
analytical technique, widely used for mapping the distribution of elements in complex 
biological samples.17  Examples include the analysis of copper and zinc in liver and kidney 
sections,18,19 the mapping of copper, zinc, iron and manganese in sections of brain tissue,20-
24 and the quantification of metal binding proteins in gels following electrophoretic separation 
of blood serum.25  Recently, the technique has been applied to image the distribution of 
iodine, silver and gold in single fibroblast cells, following labelling in vitro with KI3 and gold 
and silver nanoparticles respectively.26,27  Studies have also reported the detection of 
gadolinium-based contrast agents in tumour and tissue samples.28-30 Two of these 
investigations involved a direct comparison between LA-ICP-MS and MRI, and 
demonstrated the enhanced sensitivity and spatial resolution achievable when using LA-ICP-
MS.29,30 
 
Although LA-ICP-MS clearly has remarkable sensitivity, application of this technique to 
cellular therapy depends upon cell labelling techniques that are likely to be approved for 
clinical use.  In the current study, purified human CD4+ T cells were labelled with the contrast 
agents, Omniscan® (Gadolinium diethylenetriaminepentaacetic acid bismethylamide, Gd-
DTPA-BMA) or Dotarem® (Gadolinium 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetracarboxylic acid, Gd-DOTA) that are both in routine clinical use in magnetic resonance 
imaging.  We demonstrate that human CD4+ T cells and highly purified naturally occurring 
regulatory T cells can be labelled efficiently with Gd-chelates, and that the cells can then be 
readily detected in mixed populations using LA-ICP-MS.  Importantly, both in vitro and in vivo, 
the cells retain detectable label for at least 10 days.  To the authors’ knowledge, this is the 
first application of LA-ICP-MS to track single gadolinium labelled human T cells.  
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EXPERIMENTAL 
Instrumentation and operating parameters 
Analyses were performed on a sector-field ICP-MS instrument (Element 2XR, Thermo 
Scientific, Bremen, Germany).  For solution analyses, the instrument was fitted with a 
cyclonic spray chamber (Glass Expansion, Victoria, Australia), a conical glass concentric 
nebuliser (Glass Expansion, Victoria, Australia), and a 0.25 mm I.D. probe (Elemental 
Scientific, Omaha, USA).  For laser ablation, a UP-213 laser ablation system (Electro 
Scientific Industries, Cambridgeshire, UK) was coupled to the sector-field ICP-MS instrument.  
The laser system was fitted with a low-volume, tear-drop shaped cell, which has been 
described elsewhere.31   Helium was used as an ablation gas, at a typical flow rate of 0.6 
l/min, with argon introduced through a Y-piece, at a flow rate of 0.8 l/min, after the ablation 
cell.  The system was tuned for maximum 238U signal intensity, whilst keeping the Th/U ratio 
to approximately 1, during the ablation of NIST 611 glass.  Typical operating conditions are 
given in Table 1.   
 
Cell culture and labelling 
Human peripheral blood mononuclear cells (PBMC) were isolated from a leukocyte cone 
obtained from a local blood bank.  Leukocytes were enriched by Ficoll density gradient 
centrifugation, and CD4+ cells isolated (~95-98% purity) by MACS positive selection (Miltenyi 
Biotec).  To isolate defined populations to >98% purity, cells were labelled with anti-CD4 
(Beckman-Coulter clone SFCI2T4D11), anti-CD25 (BD Biosciences clone M-A251) and anti-
CD127 (BD Biosciences clone hIL-7R-M21) antibodies and flow-sorted on a BD FACSAria 
(BD Biosciences).  After isolation, cells were plated at a density of 1 x 106 cells per well in 2 
ml of RPMI 1640 medium, supplemented with 10% human albumin, penicillin, streptomycin 
and glutamine, plus 1 x 105 U/ml human recombinant IL-2 (Proleukin, Novartis).  Each well 
also received a volume of either Gd-DTPA-BMA (Omniscan®, GE Healthcare, UK) or Gd-
DOTA (Dotarem®, Guerbet Laboratories, France).  The cells were incubated overnight (~16 
hours) at 37oC in 95% air/5% CO2.  Following the incubation period, the cells were washed 
extensively in PBS/ 2% FCS to remove any unbound label.  Cell viability was determined 
using a trypan blue assay. 
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Optimisation of the labelling dose and incubation time 
Labelling optimisation experiments for Gd-DOTA and Gd-DTPA were carried out in parallel 
using cells from the same donor.  Cell culture and sample preparation were performed in 
accordance with the procedure detailed above.  Quantification of label uptake by the cell 
population was determined using solution based ICP-MS.  For this, cells were spun down 
into pellets and then digested according to the method proposed by Yamada et al.32 and 
modified by Kerr.33  Briefly, this involved addition of 67% HNO3 (100 µl per 1x106 cells) and 
heating at 70oC for 1 hour, followed by addition of 30% H2O2 (100 µl per 1x106 cells) and 
heating at 70oC for a further 4 hours.  The samples were then evaporated to dryness under a 
stream of nitrogen, and reconstituted in 2% HNO3.  A range of calibration standards were 
prepared by dilution of a 10 ppm elemental standard solution (SPEX Certiprep Ltd., 
Middlesex, UK). 
 
For the dose optimisation study, doses of 5, 10, 20, 50, 100 and 200 µl of either Omniscan® 
or Dotarem® were added to each well, prior to incubation overnight.  This corresponds to 
0.19, 0.38, 0.75, 1.86, 3.63 and 6.72 mg Gd/ ml, and 0.20, 0.39, 0.78, 1.92, 3.74 and 7.15 
mg of Gd/ml, for the Omniscan® and Dotarem® wells respectively.  A total of three 
replicates were performed for each dose.  In addition, three control wells containing cells 
without contrast agent were prepared.  Following dose optimisation, the incubation time was 
varied using the optimum dose.  Incubation times of 0, 1, 2, 4, 8 and 16 hours were 
assessed in triplicate.  The optimum dose and incubation time were then carried forward to 
subsequent experiments. 
 
Laser ablation of single cells 
For laser ablation-ICP-MS, labelled cells were plated onto slides (Thermo Superfrost, 
Thermo Scientific, UK) using a CytoSpin (Shandon Cytospin®, Thermo Scientific, UK).  This 
was to ensure removal of the cell culture media and provide an even distribution of the cells 
across the slide, enabling single cell targeting.  In addition to the slides containing labelled 
cells, control slides containing non-labelled CD4+ cells were also prepared.  Each slide held 
approximately 50,000 cells.   Single cell identification was demonstrated by ablating 25 µm 
diameter areas at locations corresponding to cells.  This size was chosen to ensure 
sampling of the complete cell, whilst minimising the chance of overlap onto neighbouring 
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cells.  Only single cells were targeted, cells present in clusters or closer than 25 µm apart 
were disregarded.  The presence or absence of label was determined from the 157Gd signal. 
 
To simulate biological samples, where labelled cells are present amongst a background of 
non-labelled cells, slides containing mixed labelled and non-labelled cells were prepared.  
For these, the relevant dilutions were made in solution before fixing the cells onto slides.  
Ratios of 1:1, 1:10 and 1:100 were prepared as known samples, and a replicate of each was 
provided as a blind sample.  Blind samples were randomised and identified with a non-
descriptive character.  The expected ratios of these were not disclosed to the analyst until 
after the analysis was completed.   
 
In vivo and in vitro label retention 
In order to demonstrate cellular retention of the label and assess its potential for cell tracking 
studies, a 10 day in vivo mouse study was conducted.  All mouse experiments were 
conducted in accordance with the Animals (Scientific Procedures) Act 1986.  Human 
peripheral blood mononuclear cells (PBMC) were isolated from leukocyte cones.  The CD4+ 
component was isolated using the procedure described above, and these cells were labelled 
using the optimised labelling procedure.  Following labelling, the Gd-CD4+ cells were 
washed extensively and recombined with the non-CD4+ PBMC component.  Re-mixing with 
the unlabelled PMBC component was found to be necessary to ensure viability of the cells in 
the host.  The recombined cells were then injected intraperitoneally into BALB/C Rag-/- 
common-γ chain mice, at a level of 5 million cells per mouse.  At 3, 6, and 10 days post 
infusion, the spleen and blood were harvested and a peritoneal lavage was performed.  The 
extracted cells were plated onto slides for LA-ICP-MS analysis, using the CytoSpin method 
described above.  Flow cytometry (BD FACSCanto, BD Biosciences) was used to determine 
the extent of human cell reconstitution. 
 
To estimate the degree of signal loss caused by label leakage, an in vitro label retention 
study was performed in parallel to the in vivo mouse experiments, using cells from the same 
donor.  For this, the cells were washed extensively after labelling and cultured for a further 
period in vitro before re-washing and plating onto slides. 
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RESULTS AND DISCUSSION 
 
Label uptake and optimisation 
Figure 1 shows the impact of increasing the dose of gadolinium chelate on the uptake of Gd 
by human CD4+ cells.  Uptake of Gd increased in a dose-dependent manner.  A quadratic fit 
with a low second order term fitted the data; however no plateau was reached in the dose 
range examined.  Despite the higher uptake at 100 and 200 µl, a dose of 50 µl was chosen 
as the optimum (this corresponds to 1.86 and 1.96 mg Gd/ ml for Omniscan and Dotarem 
respectively).  Volumes higher than 50 µl occupied a significant portion of the 2 ml culture 
medium, which could potentially cause osmotic effects.  However, it should be pointed out 
that the cell viability was 96% or above for all doses tested.   
 
Gadolinium uptake also increased as a function of incubation time for both complexes, as 
shown in Figure 1.  The highest uptake was observed after 16 hours, which was used as the 
standard incubation time in all subsequent experiments.  Longer incubation times were not 
tested on the grounds that they might have a detrimental effect on cell viability.  As shown 
later, the labelling levels achieved were more than adequate for achieving ~100% detection 
efficiency.  A 0 hour time point was included in the study as a measure of the efficiency of 
the cell washing process.  For this, the Gd complex was added to the well and the cells 
washed immediately, thereby allowing insufficient time for label internalisation.  
Consequently, any Gd found in these samples was taken to be from incomplete removal of 
the non-internalised complex and thus represents the background in the assay.  The Gd 
content of the 0 hour samples ranged between 5 and 20 times larger than that in the non-
labelled controls.  However, this figure represents only 0.7 and 3% of the final uptake 
achieved using the optimised labelling conditions for Gd-DTPA-BMA and Gd-DOTA 
respectively.  The cell washing procedure was therefore considered sufficient to enable 
quantification of label uptake.  The optimisation experiments, shown in Figure 1, indicated 
that Gd-DTPA-BMA provides higher net Gd loading than Gd-DOTA, with an average loading 
of 1.43 x108 atoms per cell observed for Gd-DTPA-BMA compared to only 9.36 x107 atoms 
per cell for Gd-DOTA at the optimised conditions.  Therefore, Gd-DTPA-BMA was used in all 
subsequent experiments.  
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It is likely that uptake of the Gd-complexes occurred predominately by pinocytosis, as has 
been reported for other cell lines.34,35  Gadolinium internalised via this route is known to 
localise to endosomes within the perinuclear region of the cell,34 where subsequent 
detachment of Gd3+ from its chelate may occur.35  Dechelation is expected to be more 
prevalent for Omniscan than Dotarem.  As shown in Figure 2, the DTPA-BMA chelate is non-
ionic and has an open chain structure, hence providing less stable binding to Gd3+ than the 
macrocylic, ionic DOTA chelate.36  Dechelation is accelerated in the presence of phosphate 
or competing cations,37  both of which are constituents of the cell culture media.  Thus it is 
likely that by the 16 hour time point, a portion of the Gd in the culture media was also 
present as free rather than complexed Gd.  Free Gd3+ ions may be subject to a different 
route of uptake than the complexed form.  In 1999, Cheng et al. conducted a comprehensive 
study into the uptake of lanthanide 3+ ions by erythrocytes.38  Gd3+ was found to bind initially 
to membrane phospholipids, followed by a transfer to membrane proteins.  This process 
induced conformational changes in the membrane, which resulted in the formation of pores, 
facilitating the entry of Gd3+.  It is possible that this mechanism may have provided an 
additional route for Gd uptake.  Since Gd-DTPA-BMA is known to be more unstable than 
Gd-DOTA, this additional route may account for the differences between Gd uptake for the 
two chelates, particularly at the 16 hour time point. 
 
The data shown in Figure 1 was obtained using cells isolated from human PBMC by 
magnetic negative selection of CD19+ B cells and CD14+ monocytes followed by CD4 
positive selection.  Phenotypic analysis showed that the resultant populations were between 
95-98% CD4+ T cells, but they also contained ~2-5% monocytes due to low level monocyte 
expression of CD4.  In view of the fact that these cells are known to have very active 
phagocytic and pinocytic pathways, the possibility that the Gd labelling seen was due to 
preferential monocyte uptake could not be ruled out.  To address this question, human CD4+ 
T cells were purified by flow sorting to purities exceeding 99%, containing <0.2% CD14+ 
monocytes (data not shown).  The resultant populations were then labelled using the 
optimised Gd-DTPA-BMA protocol described above.  Subsequent analysis showed a 
gadolinium uptake of 4.53 x107 atoms per cell for 99.6% pure CD4+ T cells, compared with 
the 1.43 x108 atoms per cell seen for the lower purity (~95-98%) CD4+ T cells. 
 
Most of the initial focus on regulatory immune cell therapy cellular therapy has been and will 
continue to be on naturally occurring Treg (nTreg).5-7  Although these cells represent only 
~5-10% of CD4+ T cells in human peripheral blood, the actual proportion and function varies 
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considerably between individuals.  To determine the likely variability in Gd labelling of 
functional nTreg, human CD4+CD25+CD127lo T cells were flow sorted from three different 
individuals using a sort strategy known to isolate nTreg with high functional activity both in 
vitro and in humanised mouse models.39,40  The resultant populations (purity 97.9%, 98.5% 
and 98.1%, donors 1-3 respectively) were then labelled with the optimised Gd-DTPA-BMA 
protocol and analysed as described.  The labelling of these nTreg showed remarkable 
consistency with 5.06x107, 5.08x107 and 5.88x107 Gd atoms per cell detected from donors 
1-3 respectively. 
 
The above data show unequivocally that populations of non-phagocytic human T cells being 
considered for cellular therapy can be labelled with gadolinium chelates thus offering a 
potential approach for therapeutic T cell tracking.  However, determining the persistence of 
gadolinium-labelled T cells in accessible tissues such as the peripheral blood is potentially 
compromised by the presence of highly phagocytic cells such as granulocytes, neutrophils 
and monocytes.  Positive selection on the basis of CD4 would allow enrichment of 
populations likely to contain administered nTreg but as described above, monocytes would 
present a problem since they might phagocytose gadolinium from dying circulating T cells, 
thereby giving false positives.  Although flow sorting to >99% T cell homogeneity is a 
valuable research approach, cell losses would preclude this as a diagnostic strategy.  
Therefore, laser ablation–ICP-MS was evaluated for the ability to identify labelled targets at 
a single cell level where the ablation of specific, individual cells could provide a key 
advantage not available from solution analysis.  
 
Laser ablation of single cells 
Human CD4+ T cells were purified by positive selection (final purity, 97.2%) and labelled with 
Gd-DTPA-BMA as described.  Unlabelled cells cultured for 16hrs in the presence of IL-2 
served as a negative control.  Figure 3 shows the 157Gd signal intensities for the ablation of 
25 individual labelled cells (A) and 25 individual unlabelled cells (B) after deposition onto 
slides by centrifugation.  Distinct signals were observed for the ablation of the labelled cells, 
compared to only background noise for their non-labelled counterparts.  The 25 μm spot size 
and ~9 J cm-2 fluence used in these experiments ensured complete ablation of each ~10 μm 
cell in less than a second.  Therefore, each signal observed can be regarded as 
representative of the total amount of Gd per individual cell.  Figure 4 is a histogram showing 
the variation in label uptake observed when ablating 1000 individual labelled cells taken from 
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the same labelled population as used in Figure 3.  For this, the 157Gd signal intensities were 
grouped into classes, with the number of occurrences for each class plotted on the y-axis.  
Of the 1000 cells ablated, 998 gave clear signals, confirming uptake of Gd by human CD4+ T 
cells.  In the range of 0 - 1.5 x104 counts the distribution of signals was approximately 
Gaussian, with a RSD of 39%.  A small percentage (1.6%) of signals occurred outside this 
region.  These higher signals are likely to correspond to the ablation of monocytes.  
Accordingly, the number of high signals observed matches closely with the proportion of 
contaminating CD14+ monocytes (2.8%) in the input cell population.  
 
Application of the technique to cell tracking requires discrimination of labelled cells from a 
background of non-labelled cells.  In a demonstration experiment, labelled CD4+ T cells were 
mixed with non-labelled CD4+ T cells in various ratios, prior to analysis by LA-ICP-MS.  As 
shown in Table 2, the percentage labelled as determined by LA-ICP-MS matched well with 
the prepared ratios with differences probably accounted for by a combination of incomplete 
mixing and pipetting errors.  As a further test of the technique, blind ratios of labelled and 
unlabelled CD4+ T cells were prepared and the blinding only revealed after LA-ICP-MS 
analysis.  As shown in Table 2, ratios observed from the blind experiments corresponded 
with the expected ratios adding further confirmation to the reliability of the technique. 
 
In vivo and in vitro label retention 
In addition to detection, a second key characteristic for any label considered for in vivo cell 
tracking is label retention.  Therefore, Gd-DTPA-BMA labelled CD4+ T cells were cultured in 
vitro in gadolinium-free T cell growth medium containing IL-2 and samples taken daily for LA-
ICP-MS analysis.  As shown in Table 3, although the average signal intensities fell with time, 
reaching roughly 50% of the day 1 value after 10 days, the label remained detectable at all 
time points examined, with 98.8% of cells retaining sufficient Gd for detection up to 10 days 
in culture.  In view of the low background signals observed for non-labelled cells, it seems 
likely that Gd labelled cells should be detectable for periods well beyond 10 days.   
 
Although in vitro label retention is encouraging, a more important question with respect to 
cellular therapy is whether cells retain a gadolinium signal in vivo.  To address this question 
we took advantage of a well characterised humanised mouse model in which 
immunodeficient BALB/c mice lacking T cells, B cells and functional NK cells are 
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reconstituted with defined populations of human immune cells.39  These double knock-out 
(DKO) mice were reconstituted intra-peritoneally with 2x106 Gd-DTPA-BMA labelled CD4+ T 
cells together with 3x106 autologous PBMC which aid T cell reconstitution by providing 
essential T cell growth and survival factors.  At 3, 6 and 10 days after reconstitution, the 
mice were killed for recovery of the peritoneal lavage, spleen and blood.  Reconstitution in 
this model is defined as >1% human CD45+ cells in the leucocyte gate as determined by 
flow cytometry.39  In agreement with previous experience of this model which showed that 
reconstitution of spleen and blood lags behind that of the peritoneal lavage, human cells 
were not found in the spleen or blood up to day 10 (not shown).  However, human CD45+ 
cells were readily detected in the peritoneal lavage.  Example data for one of three mice 
harvested 6 days after cell administration is shown in Figure 5A.  For comparison, the lower 
histogram shows an example of non-reconstitution.  As shown in the lower dot plot, region 
P3 confirms the presence of human CD4+ T cells within the human CD45+ gate. 
 
Aliquots of each lavage sample were plated without cell purification onto slides for LA-ICP-
MS analysis.  Figure 5B shows an LA-ICP-MS plot from the lavage sample in Figure 5A 
showing identification of 5 gadolinium labelled cells.   It is notable that whilst cells analysed 
after in vitro culture were relatively uniform in size, those examined from the lavage samples 
contained significant numbers of blasting cells possibly representing T cells mounting a 
xenogeneic graft-versus-host response.  To accommodate the larger cell diameters, the 
ablation spot size was increased from 25 to 30 μm.  However, increasing the spot size made 
the selection of single cells more challenging and it is possible that some of the low signals 
in Figure 5B were caused by slight overlap of the ablated region with the edges of 
neighbouring labelled cells.  To account for the low signals, a threshold value was set at 5% 
of the average signal intensity of the corresponding in vitro sample.  Signals below this 
threshold were not included in the % labelled count. 
 
Table 4 summarises the in vivo Gd retention data for day 3, day 6 and day 10 following the 
administration of labelled CD4+ T cells and shows the percentage of labelled cells found in 
the mouse lavage samples. In each case the detection of Gd labelled cells by LA-ICP-MS 
correlated with the presence of human CD4+ T cells in the lavage.  Furthermore, at the last 
time point examined when only two mice were available (day 10), both showed clear 
reconstitution and gadolinium positive cells were unambiguously detected (Table 4).  Thus, 
both the in vitro and the in vivo data indicate that, when labelled with Gd-DTPA-BMA, human 
CD4+ T cells retain a detectable gadolinium level for at least 10 days. 
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Nephrogenic systemic fibrosis 
The potential use of gadolinium labelling for tracking immune cellular therapies would 
depend on a favourable toxicity profile for the label itself and while Gd-chelates are widely 
used in clinical MRI, one significant complication of in vivo gadolinium administration is 
Nephrogenic systemic fibrosis (NSF).  Although rare, this condition is potentially fatal and is 
characterised by “extensive thickening and hardening of the skin”.41  Studies on patients with 
impaired renal function have found a link between the intra-venous administration of 
gadolinium chelates and the onset of NSF.42,43  Consequently, the administration of 
gadolinium contrast agents for MRI imaging is contra-indicated in patients with renal 
impairment.  Thus, any proposed use of gadolinium labelling should be treated with caution, 
particularly since regulatory approval is currently being sought for cellular therapy in renal 
transplant patients.44  However, it is important to note that at the anticipated cell doses used 
in this study (3x106/kg patient body weight), the Gd exposure from the proposed labelling 
method is dramatically lower than that received during a typical MRI scan.  When taking into 
account the average cell uptake shown in the current study of ~27 fg and the anticipated cell 
dose, the likely Gd exposure from cell labelling is ~81 ng/kg.  This is over 100,000 times 
lower than the 15.2 mg/kg dose employed for MRI imaging (Omniscan is typically 
administered at a level of 0.2 ml per kg patient weight; the formulation contains 287 mg/ml 
Gd-DTPA-BMA, which equates to 76.1 mg/ml Gd).  The risk is further minimised due to the 
route of administration, since for cell labelling, the gadolinium chelates are essentially 
compartmentalised inside the cells rather than being introduced into the systemic circulation. 
 
CONCLUSION 
 
This paper represents the first application of LA-ICP-MS to perform single cell tracking of 
therapeutically administered cells.  The technique was demonstrated on an immunodeficient 
mouse model, where the Gd-DTPA-BMA label allowed discrimination of human CD4+ cells 
for up to 10 days post-administration.  A working dose of 50 µl Omniscan / 2ml well (1.86 mg 
Gd/ ml) was used for cell labelling, which was based on sufficiency for cell tracking.  
However, since Gd cell content decreases with each cell division, it may be beneficial to 
increase this dose when performing longer term tracking experiments.  Doses of up to 200 µl 
Omniscan (6.72 mg Gd/ ml) were utilised during the solution study without noticeable impact 
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on cell viability.  Assessment of the effect of Gd-DTPA-BMA on the regulatory function of T 
cells will be the subject of a future study. 
 
The detection method has several advantages over other cell tracking techniques.  Firstly, 
elemental imaging does not rely on stable binding of Gd3+ to the chelate, thus the label can 
be detected at periods where its enhancement on MRI relaxation would be lost.  Secondly, 
the use of laser ablation allows single cell targeting, removing interferences from other 
artifacts.  Thirdly, the superior detection capability of sector field ICP-MS allows detection at 
levels of 107 atoms per cell and below, compared to the value of 108 atoms per cell recently 
reported for molecular mass spectrometry.35  With improved instrumentation, which will be 
described in another paper, and the use of higher efficiency mass spectrometers, it should 
be possible to improve this detection limit by 2-3 orders of magnitude.  A further advantage 
of the technique is that if combined with fluorescently labelled antibody staining, it would be 
possible to target ablation to specific and defined cell subsets in a sample of peripheral 
blood or tissue biopsy and provide semi-quantitative data.  If applied to the tracking of Gd-
labelled CD4+CD25+ nTreg in vivo, it would thus be possible to define the proportion of cell 
therapy nTreg within the total CD4+ T cell compartment.  If immune cellular therapy is to 
progress beyond the current Phase I/II trials, such quantification will probably prove to be 
essential. 
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TABLES 
 
Table 1. Typical operating conditions for ICP-MS and LA-ICP-MS analyses. 
Parameters ICP-MS LA-ICP-MS 
ICP radio frequency (RF) power 1215 W 1260 W 
Cool gas flow rate 15.50 l min-1 15.50 l min-1 
Auxiliary gas flow rate 0.95 l min-1 0.95 l min-1
Sample gas flow rate  0.90 l min-1 0.80 l min-1
Sample uptake rate ~70 µl min-1 - 
Torch x position 3.9 mm 5.2 mm 
Torch y position 3.0 mm 2.9 mm 
Torch z position -2.5 mm -1.9 mm 
Ablation gas flow - He, 0.60 l min-1 
Laser spot size - 25 - 30 µm 
Repetition frequency - 1 Hz (single shot) 
Laser power setting - 50% 
Laser fluence - 8.97 J cm-2 
 
 
 
Table 2. The percentage of Gd labelled cells observed when performing single cell LA-ICP-
MS on slides containing various ratios of Gd labelled to non-labelled human CD4+ T cells. 
Labelled cells were identified on the basis of their 157Gd signal.  1000 cells were ablated per 
sample. 
 Labelled : Non-
labelled ratio 
% labelled cells 
identified 
% labelled cells 
expected 
K
no
w
n 
1:0 99.8 100 
1:1 39.6 50 
1:10 5.5 9.1 
1:100 0.6 1 
0:1 0.1 0 
B
lin
d 1:1 39.1 50 
1:10 5.2 9.1 
1:100 0.7 1 
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Table 3. The number of Gd labelled human CD4+ cells observed after various periods of in 
vitro culture, following labelling with the Gd chelate Omniscan®.  Individual cells (250 per 
sample) were analysed by LA-ICP-MS.  Labelled cells were identified on the basis of their 
157Gd signal. 
Day % Gd labelled cells observed 
Average signal 
/ counts 
1 100 4118
2 100 3296
3 100 2901
4 99.6 2959
5 100 2744
6 100 2473
7 99.6 2220
10 98.8 2014
 
 
Table 4. The percentage of Gd labelled cells in ex-vivo mouse lavage samples, following 
infusion of 5 million Gd labelled human CD4+ cells.  Individual cells (250 per sample) were 
analysed by LA-ICP-MS.  Labelled cells were identified on the basis of their 157Gd signal.  
Human cell reconstitution was determined by flow cytometry (BD FACSCanto, BD 
Biosciences). 
Mouse Day % Gd positive cells  (by LA-ICP-MS) 
Human cell reconstitution  
(by flow cytometry) 
1 3 13.2 not detected 
2 3 66.4 positive 
3 3 14.0 not detected 
4 6 2.0 not detected 
5 6 35.6 positive 
6 6 48.4 positive 
7 10 20.4 positive 
8 10 49.2 positive 
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FIGURES 
 
 
 
 
Figure 1. The relationship between the dose of Gd-DOTA and Gd-DTPA-BMA (top) and the 
incubation time (bottom) on the uptake of Gd atoms by human CD4+ T cells.  Uptake was 
determined using solution based ICP-MS.  Error bars show the standard error of the mean. 
 
 
 
Figure 2. Structures of the commercially available contrast agents used for cell labelling. 
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Figure 3. Signal intensities obtained when performing LA-ICP-MS on A) 25 single Gd-DTPA-
BMA labelled human CD4+ T cells and B) 25 single non-labelled human CD4+ T cells.   
 
 
 
Figure 4. Histogram showing the distribution of 157Gd signal intensities for the ablation of 
1000 Gd labelled cells.  It is speculated that the human CD4+ cells (97.2% pure in the total 
cell population) are present within the first peak, with signals outside this range (1.6% of the 
signals observed) corresponding to the ablation of phagocytic monocytes. The inset shows 
expanded view of the distribution within the first peak. 
  
18 
 
 
 
Figure 5. Human CD4+ T cells (purity 97.2%) were labelled with Gd-DTPA-BMA, washed 
extensively and administered intraperitonealy (2x106) to BALB/c immunodeficient mice 
together with 3x106 autologous PBMC.  Peritoneal lavage samples were collected for flow 
cytometry (A) and LA-ICP-MS analysis (B).  
5A - day 6 lavage data: one of three mice shown; upper left panel - leucocyte gate;  upper 
right panel - readily detected human CD45+ cells (P2 gate); lower left panel, human 
CD3+CD4+ T cells within the gated CD45+ population confirming CD4+ T cell reconstitution.  
For comparison, lower right panel shows another of the three mice with no evidence of 
human cell reconstitution.  
5B - Example data from the reconstituted lavage shown in 5A - (day 6, mouse 5 lavage), 
showing the presence of 6 Gd labelled cells.  Small peaks below the threshold value (red 
line) were not included in the % labelled count. 
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